Neuralstem in the News

 

  • “ALS Patient Is Living His Second Miracle: Follow-up stem-cell operation has more amazing results”

By Tom Henderson, Crain’s Detroit Business Blog “Big Bucks, High Tech,”
November 30, 2012

“We’ve got to turn Lou Gehrig’s disease into Lou Gehrig’s chronic illness,” Ted Harada says three months following his impactful second treatment in Neuralstem’s ALS Phase I trial. In this follow-up interview, Ted reports that there’s a spring in his step – along with increased strength, a strong grip, and ALS symptoms again “in retreat.”

View Article

 

 

  • “Can Patients Scoop Clinical Trial Results?”

By Jason Napodano, PropThink, November 13, 2012

An ex-scientist and professional investor and analyst shares insights on, and examples of, smart online and social media “detective work,” to gain additional intelligence when investing in biotech.

View Article

  • “Stem cell therapy helps paraplegic rats regain movement”

By Selina McKee, PharmaTimes, September 17, 2012

NSI-566/spinal cord injury animal research, following report in the scientific journal CELL, is reported by UK-based industry publication.

View Article

  • “Paralyzed Rats Walk Again After Stem Cell Transplant:
    The rodent recovery spurs hope that humans could one day benefit from similar treatments.”

By Susan Young, Biomedicine Editor, Technology Review, published by MIT, September 13, 2012

Susan Young, who recently reported on progress of NSI-566 cell therapy in the ongoing ALS trial, examines CELL spinal cord injury research study, noting promise of both clinical and pre-clinical trials utilizing NSI-566 neural stem cells.

View Article

  • "Neuralstem Gains on Stem Cell Therapy for Paralyzed Rats"

By Ryan Flinn, Bloomberg, September 13, 2012

“…the last piece of the puzzle…” to move Neuralstem’s human spinal cord injury trial forward is projected by Neuralstem’s CEO Richard Garr in this article focused on the SCI study published in scientific journal CELL.

View Article

Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.

Privacy and Terms ©Neuralstem, Inc. 2014

Crain’s Detroit Business explores NSI-566 next steps with ALS P.I., Dr. Eva Feldman, and reviews additional indication, Alzheimer’s disease, following promising animal research. | 8.1.14
The Wall Street Journal interviews President/CEO, Richard Garr, on patient-directed social media’s impact on trials. NSI-566/ALS patients have independently chosen to blog online. | 7.30.14
FORBES' feature quotes President/CEO Richard Garr extensively, on the differentiation and commercialization of Neuralstem’s proprietary cell technology. | November 2013
FOX Medical Team's Beth Galvin continues her NSI-566/ALS coverage at Emory with a patient’s perspective segment. Phase I patients, Ted Harada and John Conley, are featured. | 11.20.13
Bethesda Magazine feature provides rich insights on Neuralstem’s “potential wonder drug aimed specifically at rebuilding the hippocampus”: NSI-189. | November-December 2013
Practical Neurology interviews Chairman and CSO Dr. Karl Johe and P.I. Dr. Eva Feldman about the NSI-566/ALS trials in “Decreasing Progression, Increasing Function.” | October 2013
FOX News Detroit walks with NSI-566/ALS Phase I patient Ted Harada and P.I. Dr. Eva Feldman on the eve of the Phase II trial. | 8.28.13
Bioscience Technology ALS P.I. Dr. Eva Feldman and Neuralstem’s President/CEO Richard Garr in a feature that explores data from six extraordinary ALS responders – “as rare as a red wolf.” | 5.30.13
MIT's Technology Review reports on CELL SCI research showing “paralyzed rats walk again after stem cell transplant” of NSI-566, suggesting hope for treatment of spinal cord injury. | 9.13.12